Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

486 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
COVAC1 phase 2a expanded safety and immunogenicity study of a self-amplifying RNA vaccine against SARS-CoV-2.
Szubert AJ, Pollock KM, Cheeseman HM, Alagaratnam J, Bern H, Bird O, Boffito M, Byrne R, Cole T, Cosgrove CA, Faust SN, Fidler S, Galiza E, Hassanin H, Kalyan M, Libri V, McFarlane LR, Milinkovic A, O'Hara J, Owen DR, Owens D, Pacurar M, Rampling T, Skene S, Winston A, Woolley J, Yim YTN, Dunn DT, McCormack S, Shattock RJ; COVAC 1 Study Team. Szubert AJ, et al. Among authors: winston a. EClinicalMedicine. 2023 Jan 13;56:101823. doi: 10.1016/j.eclinm.2022.101823. eCollection 2023 Feb. EClinicalMedicine. 2023. PMID: 36684396 Free PMC article.
Data linkage reduces loss to follow-up in an observational HIV cohort study.
Hill T, Bansi L, Sabin C, Phillips A, Dunn D, Anderson J, Easterbrook P, Fisher M, Gazzard B, Gilson R, Johnson M, Leen C, Orkin C, Schwenk A, Walsh J, Winston A, Babiker A, Delpech V; UK Collaborative HIV Cohort Study Group. Hill T, et al. Among authors: winston a. J Clin Epidemiol. 2010 Oct;63(10):1101-9. doi: 10.1016/j.jclinepi.2009.12.007. Epub 2010 Mar 29. J Clin Epidemiol. 2010. PMID: 20347263
Differences in neuroinflammation in people who started antiretroviral treatment during primary versus chronic HIV infection: an 18kDa Translocator protein (TSPO) positron emission tomography (PET) study.
Alagaratnam J, Thornhill JP, Fan Z, Vera JH, Underwood J, Hall R, Searle G, Owen D, Edison P, Fidler S, Winston A. Alagaratnam J, et al. Among authors: winston a. J Neurovirol. 2024 Apr 4. doi: 10.1007/s13365-024-01200-3. Online ahead of print. J Neurovirol. 2024. PMID: 38575831
Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial.
Moyle G, Assoumou L, de Castro N, Post FA, Curran A, Rusconi S, De Wit S, Stephan C, Raffi F, Johnson M, Masia M, Vera J, Jones B, Grove R, Fletcher C, Duffy A, Morris K, Pozniak A; NEAT ID Foundation and the WISARD study group. Moyle G, et al. Lancet HIV. 2024 Mar;11(3):e156-e166. doi: 10.1016/S2352-3018(23)00292-8. Lancet HIV. 2024. PMID: 38417976 Clinical Trial.
Long-term efficacy and safety of a treatment strategy for HIV infection using protease inhibitor monotherapy: 8-year routine clinical care follow-up from a randomised, controlled, open-label pragmatic trial (PIVOT).
Paton NI, Stöhr W, Arenas-Pinto A, Clarke A, Williams I, Johnson M, Orkin C, Chen F, Lee V, Winston A, Gompels M, Fox J, Sanders K, Dunn DT; Protease Inhibitor monotherapy Versus Ongoing Triple therapy (PIVOT) Trial Team. Paton NI, et al. Among authors: winston a. EClinicalMedicine. 2024 Feb 10;69:102457. doi: 10.1016/j.eclinm.2024.102457. eCollection 2024 Mar. EClinicalMedicine. 2024. PMID: 38361989 Free PMC article.
Reply to 'Cognitive criteria in HIV: greater consensus is needed'.
Nightingale S, Cinque P, Dravid A, Dreyer AJ, Gisslén M, Joska JA, Kwasa J, Meyer AC, Mpongo N, Nakasujja N, Pebody R, Pozniak A, Price RW, Saylor D, Thomas KGF, Underwood J, Vera JH, Winston A. Nightingale S, et al. Among authors: winston a. Nat Rev Neurol. 2024 Feb;20(2):129-130. doi: 10.1038/s41582-024-00928-0. Nat Rev Neurol. 2024. PMID: 38228907 No abstract available.
Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials.
Orkin C, Molina JM, Cahn P, Lombaard J, Supparatpinyo K, Kumar S, Campbell H, Wan H, Teal V, Jin Xu Z, Asante-Appiah E, Sklar P, Teppler H, Lahoulou R; DRIVE-FORWARD and DRIVE-AHEAD collaborators. Orkin C, et al. Lancet HIV. 2024 Feb;11(2):e75-e85. doi: 10.1016/S2352-3018(23)00258-8. Epub 2023 Dec 20. Lancet HIV. 2024. PMID: 38141637 Clinical Trial.
Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023.
Ambrosioni J, Levi L, Alagaratnam J, Van Bremen K, Mastrangelo A, Waalewijn H, Molina JM, Guaraldi G, Winston A, Boesecke C, Cinque P, Bamford A, Calmy A, Marzolini C, Martínez E, Oprea C, Welch S, Koval A, Mendao L, Rockstroh JK; EACS Governing Board. Ambrosioni J, et al. Among authors: winston a. HIV Med. 2023 Nov;24(11):1126-1136. doi: 10.1111/hiv.13542. Epub 2023 Oct 18. HIV Med. 2023. PMID: 37849432
486 results